Determinants of Metabolic Syndrome and 5-Year Cardiovascular Risk Estimates among HIV-Positive Individuals from an Indian Tertiary Care Hospital

Table 1

Details of the study participants according to class of ART received (n = 123).

Drug class	Name of the drug	n (%)
NNTRI	Efavirenz	82 (66.7)
	Nevirapine	13 (10.6)
NRTI	Tenofovir	97 (78.9)
	Emtricitabine	65 (52.8)
	Lamivudine	54 (43.9)
	Zidovudine	26 (21.1)
	Abacavir	4 (3.3)
PI	Atazanavir/ritonavir	28 (15.4)
	Darunavir/ritonavir	2 (1.6)
	Lopinavir/ritonavir	1 (0.8)

NNRTI, non-nucleoside reverse transcriptase inhibitors; NRTIs, nucleoside reverse transcriptase inhibitors; PI, protease inhibitor.